Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 39 - General protective or antinoxious agents
Patents for A61P 39 - General protective or antinoxious agents (19,019)
01/2001
01/04/2001WO2001000145A1 Method for scavenging radicals with urocanic acid, derivatives and analogues
01/04/2001CA2375852A1 Zinc ionophores as anti-apoptotic agents
01/03/2001CN1278794A Substituted di-hydroxyl-indol derivatives as protein tyrosine kinase and as protein serine/threenine kinase inhibitors
01/03/2001CN1278726A IL-8 receptor antagonists
01/03/2001CN1278721A IL-8 receptor antagonists
01/03/2001CN1060075C Medicine for giving up drug
12/2000
12/28/2000WO2000078980A1 Method for producing plants with increased flavonoid and phenolic compound content
12/28/2000WO2000078311A1 Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
12/28/2000WO2000078143A1 Method of increasing the content of flavonoids and phenolic substances in plants
12/28/2000WO2000054754A3 Composition comprising isoquercetin and ascorbic acid in a sustained release form
12/28/2000WO2000052013A3 Thiazoloindolinone compounds
12/28/2000WO2000043495A3 33 human secreted proteins
12/28/2000CA2340319A1 Method for producing plants with increased flavonoid and phenolic compound content
12/27/2000EP1063228A1 Cycloalkene derivatives, process for producing the same, and use
12/27/2000EP1062349A2 Diisopropyl fluorophosphatase and the utilization and production thereof
12/27/2000EP1061914A1 Lipoic acid analogs
12/27/2000EP1061812A1 Food products having enhanced cocoa polyphenol content and processes for producing same
12/27/2000CN1277858A Quick action traditional Chinese medicinal prepn. for giving-up drug
12/26/2000US6166086 Small molecules that increase the conversion of food to body weight gain
12/26/2000US6166005 Heterocyclic metalloprotease inhibitors
12/26/2000US6165996 Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis
12/26/2000US6165974 Administering an effective dose of a pharmaceutical preparation comprising at least two coagulation factors which are components of a prothrombinase or of a pro-prothrombinase to the patient for the treatment of acute bleeding
12/26/2000US6165492 Intrauterine chemical necrosing method, composition, and apparatus
12/21/2000WO2000077255A1 49 human secreted proteins
12/21/2000WO2000076556A2 High dose radionuclide complexes for bone marrow suppression
12/21/2000WO2000045791A3 Method for controlling liposome size
12/21/2000DE19927574A1 Increasing content of flavonoids and phenols in plants, useful for e.g. preventing cardiovascular disease, by reducing activity of flavanone-3-hydroxylase
12/21/2000DE19927571A1 Increasing the levels of flavonoids and phenolic compounds in plants comprises treating the plants with growth-regulating 4-acyl-3,5-dioxo-1-cyclohexanecarboxylic acid derivatives
12/21/2000CA2383048A1 49 human secreted proteins
12/20/2000EP1060174A1 Nitric oxide releasing chelating agents and their therapeutic use
12/20/2000EP1059919A1 Small molecules that increase the conversion of food to body weight gain
12/20/2000CN1277197A Stable crystal salt of 5-methyl tetrahydrofolic acid
12/19/2000US6162600 Indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
12/19/2000US6162450 Uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same
12/14/2000WO2000075176A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf)
12/14/2000WO2000075144A2 Peroxynitrite decomposition catalysts and methods of use thereof
12/14/2000WO2000074729A2 Alpha or beta emitters to fragments in radioimmunotherapy
12/14/2000WO2000074675A1 Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
12/14/2000WO2000050019A3 USE OF R-ARYL PROPIONIC ACIDS FOR PRODUCING MEDICAMENTS TO TREAT DISEASES IN HUMANS AND ANIMALS, WHEREBY SAID DISEASES CAN BE THERAPEUTICALLY INFLUENCED BY INHIBITING THE ACTIVATION OF NF-λB
12/14/2000WO2000047225A3 Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
12/14/2000WO2000045769A3 Process for extracting polyphenolic antioxidants from purine-containing plants
12/14/2000CA2376729A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf)
12/14/2000CA2374001A1 Alpha or beta emitters attached to fragments in radioimmunotherapy
12/14/2000CA2373336A1 Peroxynitrite decomposition catalysts and methods of use thereof
12/13/2000EP1058692A1 Pf4 fragments and pharmaceutical compositions containing same
12/13/2000EP1058542A1 Method for producing encased spherical granular grains
12/13/2000CN1276720A Formulations and method for reducing toxicity of antineoplastic agent
12/12/2000US6160008 Pharmaceutical compositions comprising S-alkylisothiouronium derivatives
12/12/2000CA2186867C Methods of using iron chelating compounds to reduce free radical damage in mammals
12/07/2000WO2000073330A2 Method and compositions relating to insulin resistance disorders
12/07/2000WO2000073266A1 Novel antioxidants, preparation methods and uses
12/07/2000WO2000072867A2 Substantially oil-free cyclosporin compositions
12/07/2000CA2375850A1 Method and compositions relating to insulin resistance disorders
12/07/2000CA2375348A1 Novel antioxidants, preparation methods and uses
12/07/2000CA2371247A1 Substantially oil-free cyclosporin compositions
12/06/2000EP1056770A1 Novel disulfides and thiol compounds
12/06/2000EP1056475A1 Dendrimeric fullerene derivatives, method for producing same and their use as neuroprotectors
12/06/2000CN1275914A Antioxidizing composition for scavenging free radicals, pharmaceutical composition comprising the same, and process for preparing the same
12/06/2000CN1059231C Health-care beer added with bamboo leaf flavone extract
11/2000
11/30/2000WO2000071736A1 Isoflavonoid methylation enzyme
11/30/2000WO2000071585A1 Human antibodies to staphylococcus aureus
11/30/2000WO2000040241A3 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
11/30/2000CA2373751A1 Isoflavonoid methylation enzyme
11/30/2000CA2373221A1 Human antibodies to staphylococcus aureus
11/29/2000CN1275080A Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
11/23/2000WO2000069895A2 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
11/23/2000WO2000069891A2 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
11/23/2000CA2372304A1 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
11/23/2000CA2369369A1 Buforin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
11/22/2000EP0586535B1 Methods and compositions based on inhibition of cell invasion and fibrosis by dextran sulfate
11/22/2000CN1273821A Application of sesquiterpenoid as acetylcholineserase reactivator
11/22/2000CN1058633C Plant preparation and its preparing method
11/22/2000CN1058614C Galenic prepn. compsn.
11/21/2000US6150557 Compounds
11/21/2000US6150358 Useful in the treatment of disease for which the use of anti-oxidation agent is requiered such as neurodegenrative disorders
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068255A2 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application
11/16/2000WO2000067781A1 Cardioprotective composition comprising ceruloplasmin and uses thereof
11/16/2000WO2000067743A1 Radical scavenger
11/16/2000DE19907895A1 Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können Use of R-arylpropionic acids for producing drugs for treating diseases in humans and animals, which can be influenced therapeutically by inhibiting the activation of NF-kB
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/15/2000EP1051479A1 Novel steroid-activated nuclear receptors and uses therefor
11/15/2000CN1273533A I (Robinia Pseudoacacia) lectin and its uses
11/15/2000CN1058399C Health tea and health drink capable of reducing harm of nicotine
11/14/2000US6147094 Chelating agents and their metal chelates used to reduce cardiotoxic side-effects
11/14/2000US6147056 Therapy for psoriasis
11/09/2000WO2000066138A2 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
11/09/2000CA2372947A1 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
11/08/2000EP1049778A2 Recombinant proteins derived from hgf and msp
11/08/2000EP1049478A1 Composition containing propargylamine for enhancing cancer therapy
11/08/2000EP0656002B1 3-oxo-pyrido(1,2-a -)benzimidazole-4-carboxyl and 4-oxo-azepino(1,2-a -)benzimidazole-5-carboxyl derivatives useful in treating central nervous system disorders
11/08/2000CN1272784A Medicinal compositions for application to mucosa
11/08/2000CN1272500A Safflower total uranidin, its preparation and application
11/07/2000US6143783 Amino acids
11/07/2000US6143733 Drugs for central nervous system diseases such as parkinson's disease, alzheimer's disease, huntington chorea, amyotrophic lateral sclerosis and olivopontocerebellar degeneration, psychiatric diseases such as anxiety conditions, migraine
11/02/2000WO2000065346A1 Diagnosis of human kidney diseases
11/02/2000WO2000065028A2 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
11/02/2000WO2000064957A2 Differentially acting op detoxifying sponges
11/02/2000WO2000064911A1 Ligands for metabotropic glutamate receptors
11/02/2000WO2000064439A1 Use of antioxidants to mitigate radioimmunotherapy-induced radiation toxicity
1 ... 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 ... 191